



## **Replimune to Present at Two Upcoming Investor Conferences**

August 2, 2021

WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BTIG Virtual Biotechnology Conference 2021

Date: Monday, August 9, 2021

Presentation Time: 11:00 am ET

2021 Wedbush PacGrow Healthcare Virtual Conference

Panel: For Your IOnly - Progress, Challenges in Immuno-Oncology

Date: Wednesday, August 11, 2021

Presentation Time: 12:35 pm ET

### **About Replimune**

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit [www.replimune.com](http://www.replimune.com).

### **Investor Inquiries**

Chris Brinzey

Westwicke, an ICR Company

339.970.2843

[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)

### **Media Inquiries**

Lisette Steele

Verge Scientific Communications

202.930.4762 x 409

[lsteel@vergescientific.com](mailto:lsteel@vergescientific.com)

Replimune Group Inc